Idiopathic pulmonary fibrosis is an aging-associated disease with few effective therapies, and senescent cells in lung tissue are a leading suspect in what drives it. That makes fisetin an obvious compound to test. It has been tested, and the results are more mixed than most summaries admit, including one finding in the original senolytic discovery paper that cuts directly against the lung story.
Key Takeaways
- In a bleomycin mouse model of pulmonary fibrosis, fisetin reduced weight loss, inflammatory infiltration, collagen deposition, and alveolar epithelial cell senescence, acting through AMPK activation and downregulation of NF-κB and TGF-β/Smad3.
- In the 2017 paper that first identified fisetin as a senolytic, fisetin was not senolytic in senescent IMR90 cells, a human lung fibroblast line, even though it was in endothelial cells.
- A separate rodent study of chemotherapy-induced lung toxicity found fisetin helped against methotrexate injury but was “not much effective” against bleomycin injury.
- A 2025 Mayo Clinic paper engineered a synthetic flavonol roughly 50 times more senolytically potent than fisetin, implicitly acknowledging that fisetin’s own potency is a limitation for translation.
- No human clinical trial has tested fisetin for pulmonary fibrosis or any other lung disease.
The Study That Made the Case
The central paper is a 2020 study from West China Hospital testing fisetin in the bleomycin mouse model, the standard preclinical model for lung fibrosis. Fisetin-treated mice showed less weight loss, less inflammatory cell infiltration, lower inflammatory factor expression, less collagen deposition, and less alveolar epithelial cell senescence. Mechanistically, fisetin activated AMPK and downregulated NF-κB and TGF-β/Smad3 signaling[1].
The cell-culture half of that study is the more convincing part. Fisetin inhibited alveolar epithelial cell senescence and the senescence-associated secretory phenotype, which in turn reduced the transdifferentiation of fibroblasts into collagen-producing myofibroblasts. Critically, adding the AMPK inhibitor Compound C blocked the effect, establishing that AMPK signaling was actually required rather than merely correlated[1]. That is a well-designed experiment and the finding deserves to be taken seriously on its own terms.
The Finding That Complicates It
Fisetin’s reputation as a senolytic comes from a 2017 screen that found it selectively killed senescent human umbilical vein endothelial cells. The same paper reported something less frequently quoted: fisetin was not senolytic in senescent IMR90 cells, a human lung fibroblast strain, nor in primary human preadipocytes[2]. Senolytic activity turns out to be cell-type specific, and lung fibroblasts are one of the cell types where fisetin did not clear senescent cells.
That does not invalidate the bleomycin result, because the 2020 study’s mechanism was mostly about preventing alveolar epithelial cells from becoming senescent and quieting their secretory output, not about killing senescent fibroblasts. Those are two different modes of action, sometimes distinguished as senomorphic versus senolytic. But it does mean the intuitive story, “fisetin clears out senescent cells in the lung,” is not what the data show.
A Second Rodent Study Found Much Less
A 2021 study set out to test fisetin and serratiopeptidase as protectants against chemotherapy-induced lung toxicity. Against methotrexate-induced injury, fisetin at 25 mg/kg significantly raised glutathione and lowered malondialdehyde, hydroxyproline, and collagen. Against bleomycin-induced pulmonary toxicity, the authors reported fisetin “was not much effective”[3].
That is the same injury model where the 2020 study found a clear benefit. The designs differ in ways that plausibly explain the discrepancy, dose (25 vs. higher in the fibrosis study), route (oral gavage here), and duration (14 days here, which is short for fibrosis to develop and resolve). Still, when one paper finds a robust effect in a model and another finds close to nothing, the honest summary is that the effect is not yet reliably established, not that the positive result is the real one and the null result is noise.
What the Newest Work Implies About Potency
In 2025 a Mayo Clinic group published medicinal chemistry work optimizing flavonols for senolytic activity, producing a synthetic compound (F-4N) with roughly 50 times greater senolytic potency in vitro than fisetin or quercetin. In bleomycin lung fibrosis models, F-4N reduced senescence burden, resolved chronic fibrosis, and improved markers of alveolar epithelial repair[4].
Read from a supplement buyer’s perspective, this is an important signal. A lab at the institution that ran the first human fisetin trials looked at the natural flavonols, judged their potency insufficient for translation, and built something 50 times stronger. The natural compound is the starting point for drug development, not the finished product.
What This Means If You Have a Lung Condition
There is no human trial data for fisetin in pulmonary fibrosis, IPF, COPD, asthma, or any other lung disease. IPF in particular is a serious, progressive condition with approved antifibrotic drugs that have actual human outcome data behind them. Substituting or delaying that treatment for a supplement based on mouse studies would be a genuinely bad trade, and self-directing supplementation alongside those drugs raises interaction questions that a pulmonologist should answer rather than a website.
Practical Takeaway
The bleomycin study is real, well-controlled, and interesting. It sits alongside a null result in the same model, a discovery-paper finding that fisetin does not clear senescent lung fibroblasts, and a 2025 effort to replace fisetin with something far more potent. Taken together the lung evidence is a promising early research thread rather than a reason to take fisetin for your lungs.
References
- Fisetin Alleviated Bleomycin-Induced Pulmonary Fibrosis Partly by Rescuing Alveolar Epithelial Cells From Senescence. Front Pharmacol (2020). PMID 33381023
- New agents that target senescent cells: the flavone, fisetin, and the BCL-XL inhibitors, A1331852 and A1155463. Aging (Albany NY) (2017). PMC5391241
- Amelioration of Bleomycin and Methotrexate-Induced Pulmonary Toxicity by Serratiopeptidase and Fisetin. Nutr Cancer (2021). PMID 33353415
- Optimized Synthetic Flavonols Support Senescence Clearance and Lung Fibrosis Resolution. ACS Pharmacol Transl Sci (2025). PMID 40969882
- Fisetin as a senotherapeutic agent: Evidence and perspectives for age-related diseases. Mech Ageing Dev (2024). ScienceDirect
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
